PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026

Key Takeaways

• Early ropeginterferon use yields 76.9% 2‑year PFS vs 43.1% delayed
• Integrated SURPASS‑ET/EXCEED‑ET shows consistent responses across mutations
• Switch from anagrelide improves hematologic parameters within 12 weeks
• Meta‑analysis suggests higher initial dose accelerates PV response

Pulse Analysis

The forthcoming presentations at ASCO and the European Hematology Association place ropeginterferon alfa‑2b at the forefront of essential thrombocythemia research. By comparing continuous treatment from baseline with delayed initiation after anagrelide, the SURPASS‑ET study provides compelling evidence that earlier interferon exposure not only sustains platelet control but also translates into a 33‑percentage‑point advantage in two‑year progression‑free survival. This benefit aligns with a broader trend toward front‑loading disease‑modifying agents in myeloproliferative neoplasms, where molecular remission increasingly drives long‑term outcomes.

Beyond timing, the integrated SURPASS‑ET and EXCEED‑ET analysis underscores the drug’s versatility across patient subgroups. The data set, which includes treatment‑naïve and previously treated individuals, shows uniform hematologic and molecular responses regardless of JAK2, CALR or MPL driver mutations, and even in the presence of additional non‑driver alterations. Such consistency mitigates concerns about genotype‑specific efficacy and supports a label expansion that could simplify therapeutic decision‑making for clinicians managing heterogeneous ET populations.

Regulatory and commercial implications are significant. With a supplemental biologics license application slated for FDA review and a PDUFA goal of August 30, 2026, approval would add an interferon‑based option to the limited ET armamentarium, currently dominated by hydroxyurea and anagrelide. The real‑world veteran cohort analysis and the dosing‑strategy meta‑analysis further enhance the product’s value proposition by addressing safety monitoring and optimizing early response. If cleared, BESREMi® could capture a sizable share of the global MPN market, leveraging its existing orphan‑drug status and approvals in more than 40 countries to accelerate adoption across North America and Europe.